LivaNova Drives For Certainty And Speed: Q&A With CEO Damien McDonald
Executive Summary
Damien McDonald has been CEO of LivaNova since January 2017. Speaking to In Vivo during the group’s Investor Day in mid-September, he described his efforts to transform the group and leverage its innovative cardiac surgery and neuromod technologies, and conveyed his drive to attract and develop talent.
You may also be interested in...
LivaNova Builds Strategic Base And Commercial Case To Silence Skeptics
Medical innovator LivaNova has a new stated focus: it won’t go outside the head and the heart when it comes to potential M&A and technology development projects. It has set out short- and longer-term solutions to boost sales and/or profitability in its neuromodulation and cardio franchises. What is certain is that eight months into his tenure as CEO, Damien McDonald is stamping his imprint all over LivaNova.
The Sustainability Stakes Are Rising: ‘We Cannot Recycle Our Way Out Of This’
The journey to Net Zero, described as ‘the defining issue of our time,’ will get harder in the coming decade. Failure to keep up the pressure will result in more long-term health conditions, increasing deaths and higher costs. The UK NHS is a Net Zero exemplar globally, but without a systemic approach, its compliance efforts could stutter.
UK Life Sciences Cautiously Upbeat For Investment Year Ahead – BioWales 2024
Favorable UK biopharma investment trends have been reported by the BioIndustry Association, but can medtech and healthtech share in the positivity? A roundtable at the BioWales in London 2024 event framed the outlook for non-pharma players.